Bluestein R H & Co. purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,175 shares of the company’s stock, valued at approximately $635,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in shares of Zoetis by 3.9% during the 2nd quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock worth $2,338,957,000 after purchasing an additional 1,412,829 shares during the period. Vanguard Group Inc. boosted its holdings in Zoetis by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock valued at $2,099,379,000 after acquiring an additional 910,265 shares during the period. State Street Corp boosted its holdings in Zoetis by 4.9% during the 1st quarter. State Street Corp now owns 21,256,557 shares of the company’s stock valued at $1,134,453,000 after acquiring an additional 986,680 shares during the period. Morgan Stanley boosted its holdings in Zoetis by 182.5% during the 1st quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock valued at $780,119,000 after acquiring an additional 9,442,207 shares during the period. Finally, Alliancebernstein L.P. boosted its holdings in Zoetis by 55.4% during the 2nd quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock valued at $646,905,000 after acquiring an additional 3,695,449 shares during the period. Institutional investors and hedge funds own 93.20% of the company’s stock.

A number of brokerages recently commented on ZTS. BMO Capital Markets cut Zoetis from an “outperform” rating to a “market perform” rating and raised their target price for the company from $64.00 to $65.00 in a report on Tuesday, June 13th. They noted that the move was a valuation call. Cowen and Company set a $70.00 target price on Zoetis and gave the company a “buy” rating in a report on Monday, July 17th. Cantor Fitzgerald set a $75.00 target price on Zoetis and gave the company a “buy” rating in a report on Monday, August 14th. Stifel Nicolaus restated a “buy” rating and set a $65.00 target price on shares of Zoetis in a report on Friday, July 21st. Finally, CL King began coverage on Zoetis in a report on Friday, May 26th. They set a “buy” rating and a $71.00 target price for the company. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $65.44.

Zoetis Inc. (NYSE ZTS) traded down 0.12% during midday trading on Friday, reaching $64.16. The company’s stock had a trading volume of 1,538,406 shares. The company has a market capitalization of $31.38 billion, a P/E ratio of 36.27 and a beta of 1.02. Zoetis Inc. has a 1-year low of $46.86 and a 1-year high of $65.83. The company has a 50 day moving average of $62.44 and a 200-day moving average of $59.64.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The company had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the prior year, the business earned $0.49 earnings per share. The company’s revenue was up 5.0% compared to the same quarter last year. Equities research analysts anticipate that Zoetis Inc. will post $2.34 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Bluestein R H & Co. Purchases New Holdings in Zoetis Inc. (ZTS)” was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/bluestein-r-h-co-purchases-new-holdings-in-zoetis-inc-zts/1582969.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.